Medulloblastoma (MB) is an embryonic brain tumour that arises in the cerebellum. Using several MB cell lines, we have demonstrated that the chemotherapeutic drug etoposide induces a p53-and caspase-dependent cell death. We have observed an additional caspase-independent cell death mechanism involving delayed nuclear factor jB (NF-jB) activity. The delayed induction was controlled by a p53-dependent transcription step and the production of death receptors (especially CD95/Fas). We further demonstrated that in both MB and glioblastoma (GM) cell lines, in which the p53 pathway was not functional, no p65 activation could be detected upon etoposide treatment. MB cell lines that have mutations in p53 or NF-jB are either less sensitive (NF-jB mutant) or even completely resistant (p53 mutant) to chemotherapeutic intervention. The optimal cell death was only achieved when both p53 and NF-jB were switched on. Taken together, our results shed light on the mechanism of NF-jB activation by etoposide in brain tumours and show that the genetic background of MB and GM cells determines their sensitivity to chemotherapy and has to be taken into account for efficient therapeutic intervention.
Medulloblastoma (MB) is the most common malignant brain tumour in children. 1 It is a primitive neuro-ectodermal tumour, arising from neural stem cell precursors in the granular cell layer of the cerebellum. Current treatments include different combinations of surgical resection, craniospinal radiotherapy and chemotherapy. The survival rate as a function of the tumour stage is between 60 and 80%. However, despite the efficiency of current treatments, survivors still suffer significant long-term after-effects and children younger than 3 years old have a less favourable prognosis as some therapy modalities are not possible. 2 Etoposide is one of the currently used clinical chemotherapeutic agents. It damages DNA by stabilising the DNA-topoisomerase II complex, thus increasing the frequency of double-stranded DNA breaks. However, tumours display different sensitivities to this drug and the molecular mechanisms of resistance are largely unknown. Etoposide has previously been shown to activate the proinflammatory nuclear factor kB (NF-kB)-dependent signalling pathway, 3, 4 the tumour suppressor p53 transcription factor, 5 as well as the death receptor (DR) Fas expression. 6 NF-kB is a family of transcription factors; RelA/p65, the main member of the canonical pathway is involved in inflammation, 7 cell cycle progression 8 and tumorigenesis. 9 Yet the effects of its activity are blurred because of its dual role as a pro-or antiapoptotic factor. 10 Its role in cell death has previously been reported in several cellular models including neuroblastoma. 11, 12 p53 responds to DNA damage or deregulation of mitogenic oncogenes through the induction of cell cycle arrest, apoptosis or cellular senescence. Mutations in p53 are often associated with aggressive tumour behaviour and poor patient prognosis. 13 Previous investigations have indicated potential crosslink between p53 and NF-kB pathways, but relatively few studies explore the molecular mechanisms involved. The best described mechanisms of crosstalk are (1) direct competitive interaction between p53 or p65 with the transcriptional coactivator proteins p300 and CREB-binding protein (CBP), [14] [15] [16] and (2) the recruitment of the non-canonical NF-kB member p52 by p53 and subsequent regulation of p53-dependent genes. 17 We demonstrate here, for the first time, a new molecular bridge between NF-kB and p53 that involves transcription and expression of DRs. The DR family includes Fas (CD95/APO-1), death receptor 3-6 (DR3-6) and tumour necrosis factor-R1 (TNF-R1) receptors. A shared feature of DRs is a conserved 80 amino-acid sequence, the death domain, in the cytoplasmic tail of these molecules.
Upon activation of Fas, sequential association of the adaptor molecule Fas-associated via death domain (FADD) and proforms of caspase 8 lead to the death signalling. 18 We have observed a delay in p65 activation following etoposide treatment compared with the classical TNFa activator, due to an essential transcription/translation mechanism. We have further identified p53 and Fas as key mediators of this activity in MB cells. We have used different MB cell lines (D283-MED, MHH-Med1, MEB-Med8A and D458-MED cells) that bear differential mutation status in the NF-kB and/or p53 genes, and showed that they are correlated to differential sensitivity to chemotherapeutic treatment. Similar results were obtained in some glioblastoma (GM) cell lines (D566-MG, U87MG and T98G cells). Altogether our data strongly suggest a clear molecular mechanism for etoposide-induced cell death in brain tumours, which ought to be taken into account to maximise the efficiency of clinical management.
Results
Etoposide induces a delayed p65 activation in MB cells. Etoposide has previously been shown to activate p65. 3, 19 We have probed this activation in MB cells by western blot with an anti-phospho-Ser536 p65 antibody. We observed p65 phosphorylation 6 h after etoposide treatment in D283-MED and D458-MED cells. Interestingly, this phosphorylation was not observed in MHH-Med1 or in MEB-Med8A cell lines (Figure 1a ). This phosphorylation event was further correlated with p65-dependent transcription. Using luminometry, we have shown that only D283-MED and D458-MED cells displayed an etoposideinduced NF-kB-dependent transcriptional activity ( Figure 1b) . As a positive control, TNFa was used to show that NF-kB could be induced in these cells. It was found that MHH-Med1 cells did not respond to TNFa, but all of the other three cell lines showed the expected NF-kB response ( Figure 1d and e and Supplementary Figure S1A-C). Despite the observation that Ser536 phosphorylation is essential for p65 activity, we further analysed the absence of NF-kB induction upon TNFa treatment in MHH-Med1 cells. We showed that 10 ng/ml of TNFa was unable to induce inhibitor of nuclear factor kBa (IkBa) degradation, p65 nuclear translocation and NF-kB-dependent transcription (Supplementary Figure S1D-F) .
We then used the D283-MED cells as a model cell line and probed the role of IkB Kinases (IKKs) and IkBa in etoposideinduced p65 phosphorylation. Treatment of D283-MED cells with the IKKs inhibitor BMS-345541 or IkBa inhibitor Bay11-7082 inhibited etoposide-induced p65 phosphorylation (Figure 1c) , showing the essential function of IKKa/b and IkBa in etoposide-induced p65 signalling. The dynamics of p65 activation and translocation into the nucleus were also examined using time-lapse confocal microscopy of single living cells transfected with vectors encoding p65-RedXP and IkBa-enhanced green fluorescent protein (EGFP) fluorescent fusion proteins ( Figure 1d ). As previously demonstrated in other cell lines, 4, 20 we observed damped p65 nuclearcytoplasmic oscillations after TNFa treatment. The first peak of nuclear occupancy was at B60 min after TNFa treatment. Following etoposide treatment, p65 translocation into the nucleus was delayed by 1 h and the peak amplitude was reduced (Figure 1d ). The delay in p65 activation was confirmed by western blotting (Supplementary Figure S1A) and by luminescence imaging (Figure 1e ) using a NF-luciferase reporter vector containing 5 repeats of NF-kBbinding sites cloned upstream of the luciferase gene. The presence of a delay suggested that p65 activation might be indirect. To determine if the delay was caused by an earlier transcriptional and/or translational event, we inhibited transcription with actinomycin-D (Figure 1f ) or translation with cycloheximide (Supplementary Figure S2) 30 min before TNFa/etoposide treatment. Etoposide-induced p65 phosphorylation was prevented by both inhibitors, suggesting that a first transcription/translation event was essential for etoposideinduced p65 activation. As expected, the inhibition of transcription/translation did not affect TNFa-induced p65 phosphorylation.
Medulloblastoma cell lines displayed different sensitivity to etoposide involving both caspasedependent and -independent programmes. The effect of etoposide on cell viability in different MB cell lines was assessed using the 3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay (Figure 2a ). This showed that these cell lines displayed a different sensitivity to etoposide treatment. We observed B80% of cell death 24 h after treatment in both D283-MED and D458-MED cells, whereas MHH-Med1 displayed only 58% of death at the same time. Conversely, MEB-Med8A cells were strongly resistant to etoposide treatment up to 24 h. We next investigated the role of p65 activity in the cell death programme activated by etoposide. Inhibition of NF-kB pathway in D283-MED cells was obtained either with various NF-kB inhibitors (Wedelolactone: IKK complex inhibitor; Bay11-7082: IkBa inhibitor; JSH-23: p65 nuclear translocation inhibitor) or by using p65 siRNA. This inhibition partially or totally prevented etoposide-induced cell death (Figure 2b and c) , suggesting a key role for NF-kB in etoposide-induced cell death in these cells. Similar results were obtained for D458-MED cells (not shown). In contrast, MHH-Med1 cells (in which no p65 activity could be detected) were not protected by NF-kB inhibition (Supplementary Figure S3A) .
To further characterise the type of cell death induced by etoposide, we measured the caspase 3/7 activity in each cell line (Figure 2d ). In accordance with the viability assay, we observed strong and fast caspase-3 activation in D283-MED and D458-MED cells; however, no caspase-3 activation could be observed in MEB-Med8A until 24 h after etoposide treatment. This was in line with the resistance of this cell line to etoposide-induced cell death. Surprisingly, MHH-Med1 cells displayed a stronger caspase activity compared with D283-and D458-MED cells, although lower cell death was observed in these cells (Figure 2a and d) . This suggests the involvement of a different cell death mechanism, which was independent of caspase-3 activation. Evidence to support this hypothesis was that blocking NF-kB activity with Bay11-7082 did not prevent caspase-8 or 3/7 induction (Figure 2e ), but protected the cells from etoposide cytotoxicity (Figure 2b ). These data suggest that p65 may be involved in a caspaseindependent cell death pathway that may enhance another form of etoposide-induced caspase-dependent cell death. Etoposide-induced cell death was further characterised by an annexin V-propidium iodide assay and we observed by flow cytometry both apoptosis and necrosis (not shown). An assay of macroautophagy induction by acidic vacuoles staining with the monodansylcadaverine dye suggested some autophagy induction (Supplementary Figure S4) . Figure S3C ). These results indicated that p53 induction was a prerequisite for two distinct death pathways triggered by etoposide: one that was caspase-dependent and the other that was p65-dependent but caspase-independent.
The expression of Fas DR is required for p65 phosphorylation. To further elucidate the link between p53-dependent transcription and p65 activity, we have screened by qPCR several p53-dependent genes upon 6 h of etoposide treatment. We observed in D283-MED, D458-MED and MHH-Med1 cells an induction of several DRs Figure S6B) . We then investigated the role of Fas receptor in p53/p65 crosstalk. D283-MED cells were transfected with a Fas siRNA for 48 h and treated with etoposide for an additional 6 h. Fas receptor knockdown strongly inhibited p65 phosphorylation (Figure 4e ). To probe in detail the mechanism of Fas activation, we inhibited the interaction between Fas receptor and its ligand (FasL). However, treatment with the Fas antagonist antibody ZB4 or the inhibitory peptide Kp7-6 did not inhibit etoposide-induced cell death (Figure 4f and Supplementary Figure S7A , B) or p65 phosphorylation (Figure 4g and Supplementary Figure S7C) . These results suggested that Fas receptor-induced p65 activation was independent of FasL. This finding was confirmed by the absence of FasL amplification by qPCR (Supplementary Figure S7D) and by the fact that no FasL could be detected by ELISA (not shown). Interestingly, similar observations have been described in other MB cell lines 22 and suggest an important role of receptor oligomerisation in Fas receptor activity.
The upstream role of p53 in cell death sensitivity also takes place in GM cells. To probe the generality of our findings in other central nervous system tumour cells, further experiments were performed in GM cell lines (D566-MG, T98G and U87MG cells). Interestingly, different sensitivities were also observed upon etoposide treatment (Figure 5a ), and were again correlated with the activation status of p53 and NF-kB signalling pathways. Indeed, D566-MG and T98G GM cells were found to be unable to accumulate p53 after etoposide treatment (Figure 5b ) and consequently no Fas expression (Figure 5c ) or p65 phosphorylation (Figure 5b ) could be detected. The impairment in p53-and p65-dependent signalling was also confirmed by the absence of induction of specific target genes (mdm2 and IkBa, Figure 5c ). These cells were strongly resistant to etoposide-induced cell death as previously observed with the MB MEB-Med8A cells (Figures 2a and 5a ). U87MG GM cells showed p53 accumulation ( Figure 5b (Figure 5a ). In contrary to the MHH-Med1 cells, the absence of p65 activation in U87MG is not due to an impairment of the NF-kB pathway, as TNFa treatment was able to induce IkBa degradation, p65 phosphorylation and translocation into the nucleus (Figure 5d and Supplementary Figure S8 ). The two other GM cell lines (D566-MG and T98G) displayed a normal p65 activation and IkBa degradation upon TNFa stimulation similarly to MEB-Med8A cells (Figure 5d and Supplementary Figure S8 ). The role of p53, Fas and p65 and the consequences on cell death of mutations at different levels of the signalling cascade in both MB and GM cells are summarised in the diagram Figure 6 .
Discussion
Delay in NF-jB induction by etoposide, role of the p65-p53 crosstalk. Our results describe a new mechanism of crosstalk between the p53 and NF-kB signalling pathways through DRs production. This finding may also explain the mechanism by which MB cell lines show differential resistance to etoposide treatment. Previous studies in leukaemia and neuroblastoma cells have described etoposide-induced NF-kB activation. 4, 19, 23 In those studies NF-kB inhibition was enhancing etoposide-induced apoptosis, whereas we show here a protection of MB cells using three different NF-kB inhibitors acting at different levels of the signalling pathway or by p65 knockdown with siRNA. This role of NF-kB in triggering cell death has previously been observed in osteosarcoma cell line. 12 The difference suggests a tumour-dependent role of p65.
A delayed NF-kB activation has previously been reported using two different stimuli (etoposide and FasL), 19, 24 although the mechanism of this delay was not described. The NF-kB activation observed in this study indicates the involvement of IKKa/b and IkBa (Figure 1c) as both BMS-345541 and Bay11-7082 inhibited etoposide-induced p65 phosphorylation. Furthermore, inhibition of either transcription or translation also prevented p65 activation and we have identified p53 and Fas receptor as key upstream proteins. p65-p53 crosstalk has previously been reported. A direct competition with the CBP/p300 proteins, [14] [15] [16] whereby p53 down-regulates NF-kB transcription is well documented. This cannot be the case in the system studied here as: (1) p53 inhibition abolished NF-kB activation (Figure 3c and Supplementary Figure S5) ; and (2) no NF-kB activity could be detected in cells were p53 was defective (MEB-Med8A cells). Bohuslav et al. 25 have suggested another mechanism, in which p53 activation is able to induce Ser536 p65 phosphorylation and nuclear translocation through the ribosomal S6 Kinase 1 (Rsk1). This is proposed to be independent of IKK activation and IkBa degradation. We cannot exclude the implication of Rsk1 in our model, yet it is unlikely to be of primary importance as (1) the etoposideinduced p65 phosphorylation is dependent of IKKs activity (Figure 1c) , (2) We have observed IkBa degradation following etoposide treatment (not shown) and (3) p65 activation is dependent on a transcriptional event (Figure 1f ). This was not the case in the results reported by Bohuslav et al.
25
Etoposide-induced NF-kB activation appeared to be weaker than that from TNFa stimulation as judged by a lower nuclear translocation amplitude and level of phosphorylation 19 ( Figure 1d and Supplementary Figure S1A ) and indicates that other mechanisms than the ones occurring upon TNFa stimulation are involved. It could be argued that the observed NF-kB activation might in turn modulate p53 activity as a negative feedback loop. 26 This hypothesis was tested by siRNA knockdown of p65 and no change in etoposide-dependent p53 activation was observed (Supplementary Figure S9 ). However, the cross-regulations between the NF-kB and p53 are likely to be highly complex and dynamic and could also be more subtle and dependent on the stimuli.
Death receptors as a bridge between p53 and NF-jB. It has been previously shown in vascular smooth muscles cells that p53 can induce a rapid expression of Fas to the plasma membrane from the Golgi, without new RNA and protein synthesis. 27 However, we have here observed a (Figure 4d ). An interesting finding is the involvement of the DR in a ligand-independent manner. We used two different approaches using the specificity of the antagonist antibody ZB4 and the antagonist peptide Kp7-6 (Figure 4f and g and Supplementary Figure S7) . We showed no effects of inhibition of Fas-FasL interaction on etoposide-mediated cell death and p65 activation. We therefore checked the presence of FasL expression by ELISA and qPCR. Surprisingly, we did not detect any increase of FasL expression upon etoposide treatment; moreover, we did not detect any basal expression either, compared with two other human cancer cell lines (Supplementary Figure S7D) . However, the Fas receptor knockdown by siRNA completely inhibited the etoposideinduced p65 phosphorylation (Figure 4e) . Altogether, these results suggest that the strong overexpression of Fas induces a ligand-independent oligomerisation allowing the activation of downstream signalling. It was commonly thought that membranous receptors were in a monomeric form at the membrane, and that oligomerisation was induced by the ligand. However, it has been shown that TNF receptor family members can assemble in a ligand-independent manner to form a preoligomerised complex at the plasma membrane. 28 In addition, more recent work has shown a similar process, in which Fas was able to induce ligandindependent signalling. 29 We have also shown that the overexpression of Fas receptor was sufficient to induce cell death in D283-MED but not in MHH-Med1 cells (Supplementary Figure S10) .
Despite few studies describing a caspase-dependent inhibitory effect of Fas on NF-kB, 30, 31 it is usually accepted that Fas induces NF-kB. 24, 32 This activation involves the adaptor protein FADD, caspase-8 and RIP. Although FADD is likely involved in our signalling cascade, the role of caspase-8 is less clear as caspase-8 inhibition did not inhibit p65 phosphorylation (Supplementary Figure S11) . This is in line with the recent study from Neumann et al., 33 who have clearly demonstrated that Fas activates in parallel the caspases (8 and 3) and the NF-kB activity and that blocking the caspases did not impair p65 activation. They have also shown the direct activation of the IKK complex through Fas-associated death domain-like interleukin-1b-converting enzyme-like inhibitory protein (p43-FLIP) formation upon Fas activation, confirming our findings on the role of IKK in etoposide-induced NF-kB activity by Fas recruitment. These results coupled with the role of p65 in MB cell death (Figure 2b and c) support the involvement of a non-apoptotic cell death to enhance efficiently the p53-dependent apoptotic cell death (Figure 3d and e). Interestingly, a non-apoptotic cell death induced by Fas receptor stimulation was previously described. 34 We have observed an induction of autophagy (Supplementary Figure S4) in the presence of etoposide, which could potentially be involved in the Fas-NF-kB-induced cell death.
We have shown by qPCR that etoposide could induce other DRs: DR3, DR4 and DR5 (Figure 4a ). As these DR and Fas are members of the TNF receptor family, a part of machinery below these receptors is common and we cannot exclude an additional role of these receptors in NF-kB activation. This is in line with previous reports showing NF-kB activation by different DRs, 35 ,36 yet in other systems, the role of NF-kB in DRs expression was also described. 37 Moreover, several studies demonstrated that DRs could have a function in chemosensitivity, notably in MB. 38, 39 In summary, our results suggest that the DR synthesis and auto-oligomerisation is likely to be involved in activation of the caspase cascade as well as in NF-kB activation. In addition, we cannot exclude the implication of other death domain proteins that could also be involved in the bridge between p53 and NF-kB. For example, p53-induced protein with death domain (PIDD) has been shown to be transactivated by p53 and to activate NF-kB upon DNA damage through sumoylation and ubiquitination of upstream NF-kB modulators. 40 The integrity of the p53-Fas-NF-jB signalling is required for optimal chemosensitivity of MB cells. We have demonstrated that cells expressing a fully functional connection between p53 and p65 by Fas receptor production are the most sensitive to the DNA-damaging agent etoposide ( Figure 6 ). Indeed, MEB-Med8A, D566-MG and T98G cells that are impaired in p53 signalling are strongly resistant to etoposide. Similar results were described in neuroblastoma. 41 Interestingly, in MHH-Med1 and U87MG cells that bear an apparently normal p53 signalling, but are unable to further activate p65, we observed an intermediate sensitivity (Figures 2a and 5a and model Figure 6 ). The impairment in p53 signalling in MEB-Med8A cells is at least in part due to the absence of p53wt and the presence of a truncated isoform. This isoform could be p53b according to its molecular weight and migration pattern on western blot. 42 Regarding the MHH-Med1 cells, we have not been able to identify the reason why NF-kB phosphorylation and transcription were completely impaired in these cells even upon the classical TNFa inducer. The cells display a normal expression pattern of p65, IkBa and IKK on a western blot compared with other cell lines (not shown), suggesting a potential mutation upstream in the receptor adaptor molecules.
In conclusion, our study has depicted a new molecular mechanism for etoposide-induced cell death that has clear implications for future clinical treatments. We have shown the importance in determining biomarkers in tumour tissues to adapt the chemotherapeutic treatment in a caseby-case basis. As drug resistance is currently one major problem in chemotherapy, the elucidation of a genomic signature for each tumour should allow bypassing some resistances. Moreover, inducing concomitantly multiple death pathways may also improve considerably the treatment efficiency.
Materials and Methods
Drugs, antibodies and vectors. Protease and phosphatase inhibitor cocktails, PFTa, actynomycin-D, cycloheximide, mouse anti-IgG-Cy3 conjugate and mouse anti-Fas antibody (clone DX2, no. F4424) were from Sigma (St Louis, MO, USA). Etoposide, Wedelolactone, BMS-345541, Bay11-7082, Kp7-6 peptide, tumour necrosis factor-a (TNFa), Fas ligand ELISA kit and mouse anti-actin antibody were from Calbiochem (Darmstadt, Germany). Stealth RNAi siRNAs were from Invitrogen (Carlsbad, CA, USA), and all medium and reagents used in tissue culture were supplied by Gibco Life Technologies (Carlsbad, CA, USA). Fetal calf serum was from Harlan Seralab (Loughborough, UK). Luciferin used for luminometry and luminescence assay was from Biosynth AG (Staad, Switzerland). Mouse anti-p65 (sc-8008) and mouse anti-p53 (sc-263) antibodies p53-dependent NF-jB activation by etoposide D Meley et al
